Antibiotic Prevention of Acute Exacerbations of COPD
-
Upload
indira-bryant -
Category
Documents
-
view
42 -
download
1
description
Transcript of Antibiotic Prevention of Acute Exacerbations of COPD
![Page 1: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/1.jpg)
1
Antibiotic Prevention of Acute Exacerbations of
COPD
Dr Farhad Abbasi
Infectious Diseases Specialist
![Page 2: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/2.jpg)
2
Globally, COPD is the fourth leading cause of death.
An estimated 24 million persons in the United States have COPD on the basis of lung-function testing.
![Page 3: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/3.jpg)
The average person with COPD has one to
two acute exacerbations each year, with wide
variation from patient to patient.
3
![Page 4: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/4.jpg)
During an acute exacerbation, antibiotics are
generally administered for 5 to 10 days,
creating a national burden of 120 million to
480 million antibiotic-days annually.
4
![Page 5: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/5.jpg)
The median hospital stay per exacerbation has
been estimated at 9 days
Acute exacerbations also accelerate the
progressive decline in lung function associated
with COPD.
5
![Page 6: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/6.jpg)
COPD is characterized by chronic airway
inflammation resulting in increased mucus
production and airway ciliary malfunction.
The inflammatory process leads to destruction of
respiratory bronchioles, parenchymal loss, and
thickening of the vascular wall
6
![Page 7: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/7.jpg)
Exacerbations of COPD have been shown to
coincide with acute respiratory viral infections.
picornaviruses, influenza virus, and respiratory
syncytial virus
7
![Page 8: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/8.jpg)
At the same time, the sputum of patients with
COPD is colonized with bacteria, often with
newly acquired strains of known pathogens
such as Streptococcus pneumoniae,
Haemophilus influenzae, and Moraxella
catarrhalis.
8
![Page 9: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/9.jpg)
Members of the macrolide class of antibiotics
including erythromycin, clarithromycin, and
azithromycin inhibit bacterial RNA-directed
protein assembly by binding to the 50S
subunit of bacterial ribosomes.
9
![Page 10: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/10.jpg)
In addition to their antimicrobial efficacy,
macrolides have been shown to have
antiinflammatory and immune-modulating
effects
10
![Page 11: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/11.jpg)
A recent large clinical trial involving 1142
volunteers examined the hypothesis that daily
administration of 250 mg of azithromycin for
1 year would reduce the frequency of acute
exacerbations of COPD.
11
![Page 12: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/12.jpg)
In another long-term, placebo-controlled
clinical trial examining macrolide antibiotics in
the prevention of acute exacerbations of
COPD involving 109 patients, erythromycin
was the active drug, given at a dose of 250
mg twice daily for 1 year.
12
![Page 13: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/13.jpg)
COPD management
Smoking cessation
Enrollment in a pulmonary rehabilitation program
Use of evidence-based medications, including:
1. long-acting inhaled beta-agonists
2. long-acting inhaled anticholinergic agents
3. inhaled glucocorticoids
13
![Page 14: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/14.jpg)
A patient who continues to have frequent
acute exacerbations despite guidelines-
based treatment is a potential candidate for
prophylactic use of azithromycin
14
![Page 15: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/15.jpg)
azithromycin is an inhibitor of the
cytochrome P-450 enzyme CYP3A4, it
should not be used if the patient is taking
any drug that is metabolized by that
enzyme.
15
![Page 16: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/16.jpg)
Dose adjustment is not needed for renal dysfunction.
However, because macrolides are metabolized in
the liver, we suggest not using azithromycin if the
patient has moderate or severe liver disease, as
indicated by serum aminotransferase levels of more
than three times the upper limit of the normal range.
16
![Page 17: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/17.jpg)
we suggest follow-up evaluations every 3 months,
at which time all the initial screening, including
audiography and electrocardiography, should be
repeated. The physician should ask the patient
about hearing problems, disequilibrium, and
tinnitus, which might be signs of ototoxicity.
17
![Page 18: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/18.jpg)
since any antibiotic can select for Clostridium
difficile, the patient should be asked about
diarrhea and other gastrointestinal symptoms.
18
![Page 19: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/19.jpg)
Adverse Effects
Ototoxicity
Cardiac toxicity
Drug–drug interactions.
19
![Page 20: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/20.jpg)
Hearing loss, disequilibrium, and tinnitus
are potential adverse effects of macrolides
20
![Page 21: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/21.jpg)
Macrolide antibiotics prolong the QTc interval by
blocking a cardiac potassium channel
A prolonged QTc interval is associated with an
increased risk of torsades de pointes, potentially
resulting in ventricular fibrillation and sudden death.
21
![Page 22: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/22.jpg)
we suggest avoiding the use of azithromycin in
patients with a high risk of baseline
cardiovascular disease. Such patients include
those with congestive heart failure,
cerebrovascular disease, and peripheral
vascular disease
22
![Page 23: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/23.jpg)
Macrolides also inhibit the CYP3A4 isoenzyme,
thus increasing serum levels of other drugs
metabolized by this enzyme
1. Statins
2. Warfarin
3. amiodarone
23
![Page 24: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/24.jpg)
Long-term macrolide prophylaxis
Ddiffuse panbronchiolitis
Cystic fibrosis
Bronchiectasis
Prevention of Mycobacterium avium complex
infection in patients with the AIDS and a CD4+ <50
cells per cubic millimeter
24
![Page 25: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/25.jpg)
Some experts are promoting the idea of
screening patients with COPD for colonization
with nontuberculous mycobacteria and
withholding macrolide prophylaxis in those
with positive sputum cultures
25
![Page 26: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/26.jpg)
would suggest discontinuing the drug if
important adverse effects surface or if the
number of exacerbations does not decrease
during the first year of treatment.
26
![Page 27: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/27.jpg)
Qquinolones should not be preferred over
macrolides for COPD prophylaxis, because
they are so important for treating community-
acquired pneumonia.
27
![Page 28: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/28.jpg)
28
![Page 29: Antibiotic Prevention of Acute Exacerbations of COPD](https://reader035.fdocuments.us/reader035/viewer/2022062304/568135d4550346895d9d4039/html5/thumbnails/29.jpg)
29